62 related articles for article (PubMed ID: 16303862)
1. Continued use of trastuzumab beyond disease progression in the national comprehensive cancer network: should we practice ahead of the evidence?
Wong YN; Ottesen RA; Hughes ME; Niland JC; Theriault R; Edge SB; Blayney D; Weeks JC
Oncologist; 2011; 16(5):559-65. PubMed ID: 21450786
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review.
Blank PR; Dedes KJ; Szucs TD
Pharmacoeconomics; 2010; 28(8):629-47. PubMed ID: 20524722
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer.
Morrow PK; Zambrana F; Esteva FJ
Breast Cancer Res; 2009; 11(4):207. PubMed ID: 19664181
[TBL] [Abstract][Full Text] [Related]
4. A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis.
Norum J; Risberg T; Olsen JA
Ann Oncol; 2005 Jun; 16(6):909-14. PubMed ID: 15849222
[TBL] [Abstract][Full Text] [Related]
5. Recent trends of HER-2 examination and a new strategy of trastuzumab therapy for primary and metastatic breast cancer.
Kurosumi M
Breast Cancer; 2009; 16(4):283. PubMed ID: 19756922
[No Abstract] [Full Text] [Related]
6. Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer.
Metro G; Sperduti I; Russillo M; Milella M; Cognetti F; Fabi A
Oncologist; 2007 Dec; 12(12):1467-9; author reply 1469-71. PubMed ID: 18165625
[No Abstract] [Full Text] [Related]
7. Use of the monoclonal antibody anti-human epidermal growth factor receptor 2 (anti-HER2), trastuzumab, in the treatment of metastatic breast cancer: a cost-effectiveness analysis.
Poncet B; Bachelot T; Colin C; Orfeuvre H; Ganne C; Péaud PY; Jacquin JP; Salles B; Tigaud JD; Méchin-Crétinon I; Maréchal F; Trillet-Lenoir V
Clin Oncol (R Coll Radiol); 2007 Mar; 19(2):162-3. PubMed ID: 17357239
[No Abstract] [Full Text] [Related]
8. Reply to the article "A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model based cost-effectiveness analysis", by J. Norum et al. (Ann Oncol 2005; 16: 909-914).
Bonneterre ME; Bonneterre J
Ann Oncol; 2006 May; 17(5):875; reply 875-6. PubMed ID: 16303862
[No Abstract] [Full Text] [Related]
9. The role of trastuzumab in the management of HER2-positive metastatic breast cancer: an updated review.
Tokuda Y; Suzuki Y; Saito Y; Umemura S
Breast Cancer; 2009; 16(4):295-300. PubMed ID: 19609647
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab: targeted therapy for the management of HER-2/neu-overexpressing metastatic breast cancer.
Emens LA
Am J Ther; 2005; 12(3):243-53. PubMed ID: 15891269
[TBL] [Abstract][Full Text] [Related]
11. Trastuzumab.
Perez EA; Palmieri FM; Brock SM
Cancer Treat Res; 2009; 151():181-96. PubMed ID: 19593513
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
